DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
LECITHIN
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LECITHIN
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C10H20NO8P
Molecular Weight:
313.24
AlogP:
-1.09
PSA:
111.19
HBD:
0.0
HBA:
#RotB:
12.0
Source:
DIFAMILAST
3
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Phosphodiesterase 4 inhibitor
DIFAMILAST
×
Maximum Phase:
3
First Approval:
None
UNII:
T3U32GLJ0F
Molecule Type:
Small molecule
Molecular Formula:
C23H24F2N2O5
Molecular Weight:
446.45
AlogP:
5.06
PSA:
82.82
HBD:
1.0
HBA:
#RotB:
10.0
Source:
ENSIFENTRINE
3
Small molecule
Investigational
Unknown
Unknown
Asthma; Cystic Fibrosis; Severe Acute Respiratory Syndrome; Pulmonary Disease, Chronic Obstructive
Unknown
ENSIFENTRINE
×
Maximum Phase:
3
First Approval:
None
UNII:
3E3D8T1GIX
Molecule Type:
Small molecule
Molecular Formula:
C26H31N5O4
Molecular Weight:
477.57
AlogP:
2.72
PSA:
112.87
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DIETHYLAMINE
3
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis, Knee; Pain; Sprains and Strains
Unknown
DIETHYLAMINE
×
Maximum Phase:
3
First Approval:
None
UNII:
B035PIS86W
Molecule Type:
Small molecule
Molecular Formula:
C4H11N
Molecular Weight:
73.14
AlogP:
0.62
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
2.0
Source:
CM-4307
3
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Leukemia, Myeloid, Acute; Nasopharyngeal Neoplasms; Neoplasms; Stomach Neoplasms; Carcinoma, Hepatocellular; Thyroid Neoplasms
Unknown
CM-4307
×
Maximum Phase:
3
First Approval:
None
UNII:
41XGO0VS1U
Molecule Type:
Small molecule
Molecular Formula:
C21H16ClF3N4O3
Molecular Weight:
467.85
AlogP:
5.55
PSA:
92.35
HBD:
3.0
HBA:
#RotB:
5.0
Source:
MIZORIBINE
3
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Nephritis; Nephrotic Syndrome
GMP synthase [glutamine-hydrolyzing] inhibitor
MIZORIBINE
×
Maximum Phase:
3
First Approval:
None
UNII:
4JR41A10VP
Molecule Type:
Small molecule
Molecular Formula:
C9H13N3O6
Molecular Weight:
259.22
AlogP:
-2.7
PSA:
151.06
HBD:
5.0
HBA:
#RotB:
3.0
Source:
FABOMOTIZOLE
3
Small molecule
Investigational
Unknown
Unknown
Anxiety
Unknown
FABOMOTIZOLE
×
Maximum Phase:
3
First Approval:
None
UNII:
0F8K1X115C
Molecule Type:
Small molecule
Molecular Formula:
C15H21N3O2S
Molecular Weight:
307.42
AlogP:
2.39
PSA:
50.38
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ETHYLENEDIAMINE
3
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms; Chemical and Drug Induced Liver Injury
Unknown
ETHYLENEDIAMINE
×
Maximum Phase:
3
First Approval:
None
UNII:
60V9STC53F
Molecule Type:
Small molecule
Molecular Formula:
C2H8N2
Molecular Weight:
60.1
AlogP:
-1.1
PSA:
52.04
HBD:
2.0
HBA:
#RotB:
1.0
Source:
BEVENOPRAN
3
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Constipation
Mu opioid receptor antagonist
BEVENOPRAN
×
Maximum Phase:
3
First Approval:
None
UNII:
IC58Q2EHPJ
Molecule Type:
Small molecule
Molecular Formula:
C20H26N4O4
Molecular Weight:
386.45
AlogP:
2.28
PSA:
108.59
HBD:
2.0
HBA:
#RotB:
9.0
Source:
TENOFOVIR DISOPROXIL ASPARTATE
3
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Unknown
TENOFOVIR DISOPROXIL ASPARTATE
×
Maximum Phase:
3
First Approval:
None
UNII:
F06G7ZBB70
Molecule Type:
Small molecule
Molecular Formula:
C23H37N6O14P
Molecular Weight:
652.55
AlogP:
3.04
PSA:
185.44
HBD:
1.0
HBA:
#RotB:
13.0
Source:
VORASIDENIB
3
Small molecule
Investigational
Unknown
Unknown
Glioma
IDH1/IDH2 inhibitor
VORASIDENIB
×
Maximum Phase:
3
First Approval:
None
UNII:
789Q85GA8P
Molecule Type:
Small molecule
Molecular Formula:
C14H13ClF6N6
Molecular Weight:
414.74
AlogP:
4.31
PSA:
75.62
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RETOSIBAN
3
Small molecule
Investigational
Unknown
Unknown
Premature Birth
Oxytocin receptor antagonist
RETOSIBAN
×
Maximum Phase:
3
First Approval:
None
UNII:
GIE06H28OX
Molecule Type:
Small molecule
Molecular Formula:
C27H34N4O5
Molecular Weight:
494.59
AlogP:
2.04
PSA:
104.98
HBD:
1.0
HBA:
#RotB:
6.0
Source:
FALDAPREVIR
3
Small molecule
Investigational
Unknown
Unknown
HIV Infections; Renal Insufficiency; Hepatitis C; Hepatitis C, Chronic; Virus Diseases
Hepatitis C virus serine protease, NS3/NS4A inhibitor
FALDAPREVIR
×
Maximum Phase:
3
First Approval:
None
UNII:
958X4J301A
Molecule Type:
Small molecule
Molecular Formula:
C40H49BrN6O9S
Molecular Weight:
869.84
AlogP:
6.3
PSA:
198.38
HBD:
4.0
HBA:
#RotB:
13.0
Source:
SORBINIL
3
Small molecule
Investigational
Unknown
Unknown
Diabetic Retinopathy
Aldose reductase inhibitor
SORBINIL
×
Maximum Phase:
3
First Approval:
None
UNII:
G4186B906P
Molecule Type:
Small molecule
Molecular Formula:
C11H9FN2O3
Molecular Weight:
236.2
AlogP:
0.64
PSA:
67.43
HBD:
2.0
HBA:
#RotB:
0.0
Source:
BIXALOMER
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Phosphate sequestering agent
BIXALOMER
×
Maximum Phase:
3
First Approval:
None
UNII:
3160WY51LV
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ICA-17043
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ICA-17043
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAVAPADON
3
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Dopamine D1 receptor partial agonist
TAVAPADON
×
Maximum Phase:
3
First Approval:
None
UNII:
PT4P8MJP8L
Molecule Type:
Small molecule
Molecular Formula:
C19H16F3N3O3
Molecular Weight:
391.35
AlogP:
3.56
PSA:
76.98
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DIQUAFOSOL TETRASODIUM
3
Small molecule
Investigational
Unknown
Unknown
Dry Eye Syndromes
Purinergic receptor P2Y1 agonist
DIQUAFOSOL TETRASODIUM
×
Maximum Phase:
3
First Approval:
None
UNII:
X8T9SBH9LL
Molecule Type:
Small molecule
Molecular Formula:
C18H22N4Na4O23P4
Molecular Weight:
878.24
AlogP:
-4.19
PSA:
404.45
HBD:
10.0
HBA:
#RotB:
14.0
Source:
FOLITIXORIN
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FOLITIXORIN
×
Maximum Phase:
3
First Approval:
None
UNII:
0SXY5ET48B
Molecule Type:
Small molecule
Molecular Formula:
C20H23N7O6
Molecular Weight:
457.45
AlogP:
-0.52
PSA:
193.98
HBD:
6.0
HBA:
#RotB:
7.0
Source:
SILYBIN A
3
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Immune System Diseases; Hepatitis A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis E; Melanosis; Neoplasms; Non-alcoholic Fatty Liver Disease; Depressive Disorder; Hepatitis C; Proteinuria
Unknown
SILYBIN A
×
Maximum Phase:
3
First Approval:
None
UNII:
33X338MNE4
Molecule Type:
Small molecule
Molecular Formula:
C25H22O10
Molecular Weight:
482.44
AlogP:
2.36
PSA:
155.14
HBD:
5.0
HBA:
#RotB:
4.0
Source:
BITOPERTIN
3
Small molecule
Investigational
Unknown
Unknown
beta-Thalassemia; Obsessive-Compulsive Disorder; Schizophrenia
Glycine transporter 1 inhibitor
BITOPERTIN
×
Maximum Phase:
3
First Approval:
None
UNII:
Q8L6AN59YY
Molecule Type:
Small molecule
Molecular Formula:
C21H20F7N3O4S
Molecular Weight:
543.46
AlogP:
3.94
PSA:
79.81
HBD:
0.0
HBA:
#RotB:
5.0
Source:
IPATASERTIB
3
Small molecule
Investigational
Unknown
Unknown
Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Triple Negative Breast Neoplasms
Serine/threonine-protein kinase AKT inhibitor
IPATASERTIB
×
Maximum Phase:
3
First Approval:
None
UNII:
524Y3IB4HQ
Molecule Type:
Small molecule
Molecular Formula:
C24H32ClN5O2
Molecular Weight:
458.01
AlogP:
3.1
PSA:
81.59
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ARTEMISIN
3
Small molecule
Investigational
Unknown
Unknown
Malaria
Unknown
ARTEMISIN
×
Maximum Phase:
3
First Approval:
None
UNII:
Y1R67R7XWU
Molecule Type:
Small molecule
Molecular Formula:
C15H22O5
Molecular Weight:
282.34
AlogP:
2.39
PSA:
53.99
HBD:
0.0
HBA:
#RotB:
0.0
Source:
RIVOGLITAZONE
3
Small molecule
Investigational
Unknown
Unknown
Dry Eye Syndromes; Diabetes Mellitus, Type 2
Peroxisome proliferator-activated receptor gamma agonist
RIVOGLITAZONE
×
Maximum Phase:
3
First Approval:
None
UNII:
3A3N0634Q6
Molecule Type:
Small molecule
Molecular Formula:
C20H19N3O4S
Molecular Weight:
397.46
AlogP:
3.06
PSA:
82.45
HBD:
1.0
HBA:
#RotB:
6.0
Source:
FLUOROMETHYLCHOLINE (18F)
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FLUOROMETHYLCHOLINE (18F)
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C6H15FNO+
Molecular Weight:
135.19
AlogP:
0.64
PSA:
9.23
HBD:
0.0
HBA:
#RotB:
4.0
Source:
CEFTOBIPROLE MEDOCARIL
3
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections; Bacteremia; Meningitis; Bacterial Infections; Infections; Pneumonia; Skin Diseases; Staphylococcal Infections; Staphylococcal Skin Infections
Bacterial penicillin-binding protein inhibitor
CEFTOBIPROLE MEDOCARIL
×
Maximum Phase:
3
First Approval:
None
UNII:
N99027V28J
Molecule Type:
Small molecule
Molecular Formula:
C26H26N8O11S2
Molecular Weight:
690.67
AlogP:
-0.54
PSA:
264.3
HBD:
4.0
HBA:
#RotB:
8.0
Source:
POMAGLUMETAD METHIONIL
3
Small molecule
Investigational
Unknown
Unknown
Amphetamine-Related Disorders; Psychotic Disorders; Stress Disorders, Post-Traumatic; Schizophrenia
Metabotropic glutamate receptor 2 agonist
POMAGLUMETAD METHIONIL
×
Maximum Phase:
3
First Approval:
None
UNII:
3V85EZ3KFQ
Molecule Type:
Small molecule
Molecular Formula:
C12H18N2O7S2
Molecular Weight:
366.42
AlogP:
-1.87
PSA:
163.86
HBD:
4.0
HBA:
#RotB:
7.0
Source:
CILEXETIL
3
Small molecule
Investigational
Unknown
Unknown
Hypertension
Unknown
CILEXETIL
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C10H18O3
Molecular Weight:
186.25
AlogP:
2.88
PSA:
35.53
HBD:
0.0
HBA:
#RotB:
2.0
Source:
ENCENICLINE
3
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Liver Diseases; Psychotic Disorders; Schizophrenia; Alzheimer Disease; Dementia
Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist
ENCENICLINE
×
Maximum Phase:
3
First Approval:
None
UNII:
5FI5376A0X
Molecule Type:
Small molecule
Molecular Formula:
C16H17ClN2OS
Molecular Weight:
320.85
AlogP:
3.38
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
2.0
Source:
RVX000222
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
RVX000222
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIMETROPIUM
3
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CIMETROPIUM
×
Maximum Phase:
3
First Approval:
None
UNII:
1N3H74AYTK
Molecule Type:
Small molecule
Molecular Formula:
C21H28NO4+
Molecular Weight:
358.46
AlogP:
1.84
PSA:
59.06
HBD:
1.0
HBA:
#RotB:
6.0
Source:
DRINABANT
3
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Schizophrenia
Cannabinoid CB1 receptor antagonist
DRINABANT
×
Maximum Phase:
3
First Approval:
None
UNII:
61S98RLL5I
Molecule Type:
Small molecule
Molecular Formula:
C23H20Cl2F2N2O2S
Molecular Weight:
497.39
AlogP:
5.51
PSA:
40.62
HBD:
0.0
HBA:
#RotB:
6.0
Source:
RUPATADINE
3
Small molecule
Investigational
Unknown
Unknown
Mastocytosis; Arthritis, Rheumatoid; Hypersensitivity; Urticaria
Histamine H1 receptor antagonist
RUPATADINE
×
Maximum Phase:
3
First Approval:
None
UNII:
2AE8M83G3E
Molecule Type:
Small molecule
Molecular Formula:
C26H26ClN3
Molecular Weight:
415.97
AlogP:
5.63
PSA:
29.02
HBD:
0.0
HBA:
#RotB:
2.0
Source:
MK-0557
3
Small molecule
Investigational
Unknown
Unknown
Schizophrenia; Obesity
Neuropeptide Y receptor type 5 antagonist
MK-0557
×
Maximum Phase:
3
First Approval:
None
UNII:
HVE36P8422
Molecule Type:
Small molecule
Molecular Formula:
C22H19FN4O3
Molecular Weight:
406.42
AlogP:
3.6
PSA:
86.11
HBD:
1.0
HBA:
#RotB:
3.0
Source:
HENAGLIFLOZIN
3
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Diabetes Mellitus, Type 2
Sodium/glucose cotransporter 2 inhibitor
HENAGLIFLOZIN
×
Maximum Phase:
3
First Approval:
None
UNII:
21P2M98388
Molecule Type:
Small molecule
Molecular Formula:
C22H24ClFO7
Molecular Weight:
454.88
AlogP:
1.5
PSA:
108.61
HBD:
4.0
HBA:
#RotB:
6.0
Source:
1
2
…
136
137
138
139
140
141
142
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA